Loading
Ono Pharmaceutical is an Osaka drug company that launched the immunotherapy nivolumab (Opdivo) in Japan in 2014. It bought the US company Deciphera Pharmaceuticals in 2024.
Ono Pharmaceutical Co., Ltd. traces its origins to an apothecary opened in Doshomachi, Osaka, in 1717; the present company was established in 1947 and listed on the Osaka Securities Exchange in 1962 and the Tokyo Stock Exchange in 1963. Its headquarters are in Chuo, Osaka. In 2014 it launched OPDIVO, which its history describes as the world's first anti-PD-1 antibody, in Japan. In 2024 it acquired Deciphera Pharmaceuticals, a US company whose medicines include ripretinib.
| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-04-29 | Deciphera Pharmaceuticals (Ono) to Ono Pharmaceutical Ripretinib (Qinlock) and vimseltinib | Acquisition | not disclosed | $2.4bn | source |
Nivolumab was the second PD-1 blocker and is often combined with ipilimumab. Long-term data show about half of advanced melanoma patients alive at 10 years on the combination.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/